| Document |
Document Title |
|
WO/2024/088371A1 |
An isolated antigen-binding protein capable of targeting MSLN. The isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence represented by any ...
|
|
WO/2024/090563A1 |
The purpose of the present invention is to provide: a nucleic acid for gene expression uses, which can amplify a conditional gene expression vector stably, can be used in a gene expression analysis in a wide variety of organism species a...
|
|
WO/2024/089212A1 |
A process for the expansion of mammalian cells, the process comprising dynamically stirring cells in a bioreactor to produce an expanded cell culture, as well as products produced via said processes.
|
|
WO/2024/088412A1 |
Disclosed are a TLR7-IFN I signaling pathway activated mouse in-vivo cell, a humanized systemic lupus erythematosus mouse having the cell, a construction method for the mouse, and a use of the mouse in medical research. Specifically, a T...
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/090441A1 |
The purpose of the present invention is to provide single-round infectious particles that are derived from a virus belonging to the orthocoronavirus subfamily and in which not only the spike (S) protein on the surface of the virus belong...
|
|
WO/2024/086998A1 |
A method for regulating coagulation and/or function of platelet, by regulating formation and/or function of a microsome derived from neutrophil.
|
|
WO/2024/088386A1 |
The present application discloses the antibodies or antigen-binding fragments, and their pharmaceutical use. In particular, a monoclonal antibody according to the present application suppresses tumors, and can thus be useful as a cancer ...
|
|
WO/2024/088255A1 |
Disclosed in the present invention are a spontaneously immortalized porcine myogenic stem cell line and the use thereof, which belong to the technical field of stem cells and biological cell lines. In the present invention, porcine myoge...
|
|
WO/2024/091700A1 |
A hybrid bioelectronic implantable device containing engineered cells for delivery of therapeutic agents to a subject to treat a medical condition of the subject. The device comprises an implantable device implantable inside the subject'...
|
|
WO/2024/088404A1 |
This disclosure provides engineered 4-1BBL variants, and methods of use thereof.
|
|
WO/2024/090440A1 |
It was discovered that, by using (a) FDC in which position 397 is tryptophan, position 398 is methionine, position 440 is tyrosine, and position 189 is methionine and/or (b) FDC in which position 397 is tryptophan, position 398 is methio...
|
|
WO/2024/092181A2 |
Accordingly, the present invention relates to methods and systems for growing, expanding and/or obtaining human alveolar cells from one or both of induced-pluripotent stem cell (iPSC) derived tissue and bud tip progenitor cells derived f...
|
|
WO/2024/090832A1 |
The present invention relates to a three-dimensional (3D) neuromuscular junction (NMJ) model co-cultured with muscle bundles derived from skeletal muscle cells (C2C12) and, more specifically, to a 3D neuromuscular junction model prepared...
|
|
WO/2024/091060A1 |
According to a method for producing a brain cancer organoid from induced pluripotent stem cells derived from a brain cancer patient, a brain organoid having high production efficiency can be produced using patient-derived induced pluripo...
|
|
WO/2024/087828A1 |
The present invention relates to the technical field of cell culture and processing, and provides a PET film for cell culture in cell and gene therapy, and the use thereof. The PET film is a long-scroll-like coiled film, and forms a cyli...
|
|
WO/2024/087267A1 |
Provided is a chimeric antigen receptor capable of identifying and binding to TGFβRII. The chimeric antigen receptor is used in combination with a chimeric antigen receptor capable of identifying and binding to a tumor-specific antigen ...
|
|
WO/2024/092171A1 |
The disclosure provides a method to assemble up to four viral, e.g., adeno- associated virus (AAV), genomes in vivo in a pre-designed configuration using a DNA recombination system to provide delivery of large genes that exceed the AAV' ...
|
|
WO/2024/089293A1 |
The present invention discloses a method of therapeutically treating cancer, in particular CRC (colorectal cancer), or of reducing the risk of cancer in particular CRC, disease progression in a patient comprising expressing miR-326 in th...
|
|
WO/2024/090703A1 |
The present invention relates to an efficient natural killer (NK) cell culture method among immune cell therapies and, more particularly, to a culture method to efficiently amplify and activate immune cells after lymphocytes derived from...
|
|
WO/2024/086999A1 |
Provided is a method for regulating migrasome formation by a cell and/or migrasome-mediated biological process, comprising regulating the amount and/or function of PIP2 related pathway in said cell.
|
|
WO/2024/092015A1 |
An in vitro method of preparing a population of hypoimmune mammalian stem cells includes providing a population of isolated mammalian stem cells, wherein the isolated mammalian stem cells express a cell adhesion molecule; and modifying t...
|
|
WO/2024/090980A1 |
The present invention relates to a composition for improving bone function comprising sericin, and use thereof. The sericin of the present invention is a protein derived from a natural material, and thus not only is safe, has less denatu...
|
|
WO/2024/090458A1 |
The purpose of the present invention is to provide: a substance which has an activity of binding to an inhibitory KIR to inhibit the cytotoxic activity of an NK cell and is useful for allogeneic technologies associated with organ transpl...
|
|
WO/2024/087760A1 |
Disclosed in the present invention is a method for coupling mature erythrocytes in vitro. A drug (including macromolecules such as antibodies, polypeptides and nucleotides, and chemical molecules such as chemotherapeutic drugs) is couple...
|
|
WO/2024/090312A1 |
A production method for an artificial organ according to the present invention involves performing a decellularization treatment on a mammalian organ or a portion thereof to obtain a decellularized organ or a portion thereof and performi...
|
|
WO/2024/089622A1 |
The present application provides cord blood-derived natural killer (CB-NK) cells engineered to express chimeric receptors that target ADGRE2. Pharmaceutical compositions, kits and methods of treating cancer are also provided.
|
|
WO/2024/090673A1 |
The present invention provides a method for simultaneously performing cell culture and exosome isolation and purification by using an aqueous two-phase system during plant cell culture. Exosome production and isolation can be simultaneou...
|
|
WO/2024/090577A1 |
Provided are an animal cell culturing method and a technology related thereto. In the present invention, animal cells are cultured in the presence of a pea-derived material and/or a yeast extract.
|
|
WO/2024/059070A9 |
The invention provides a method of producing a population of CD34+ hematopoietic precursor cells. The CD34+ hematopoietic precursor cells are used in methods of producing natural killer (NK), methods of inducing NK cell differentiation f...
|
|
WO/2024/086825A2 |
Provided herein are compositions for a Herpes Simplex Virus packaging system and packaging cell line. Also provided herein are compositions, systems, and methods for producing a packaging cell line for Herpes Simplex Virus amplicons.
|
|
WO/2024/085215A1 |
Although differentiating pluripotent stem cells by temporarily differentiating the pluripotent stem cells into CTraS considerably increases the subsequent cell differentiation efficiency, it is difficult to stably induce pluripotent stem...
|
|
WO/2024/085651A1 |
The present invention relates to a medium composition for inducing differentiation from stem cells to macrophages. The medium composition for inducing differentiation from stem cells to macrophages according to one aspect, can provide th...
|
|
WO/2024/084516A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one hairpin loop structure...
|
|
WO/2024/085650A1 |
The present invention relates to a medium composition for inducing differentiation from a stem cell to a macrophage. According to a medium composition for inducing differentiation from a stem cell to a macrophage, according to one aspect...
|
|
WO/2024/084243A1 |
The invention relates to methods of non-cell autonomous modulation of reprogramming comprising providing a non-cell autonomous reprogramming factor which derives from a cell other than the somatic cell to be reprogrammed. The invention f...
|
|
WO/2024/084520A1 |
The present invention discloses a recombinant nucleic acid molecule encoded at least by an ORF (100, 100a) to lower a cytokine storm during immunotherapy. The recombinant nucleic acid molecule includes at least one first hairpin loop str...
|
|
WO/2024/083745A1 |
The current invention relates to cell - cell interaction and in particular to cellular avidity. Provided are improved means and methods to study cell - cell interaction and characterizing cellular avidity. Highly advantageously, it was s...
|
|
WO/2024/086342A1 |
The present disclosure provides methods for generating and/or purifying secretomes, extracellular vesicles, and fractions thereof, from progenitor cells; and provides compositions containing such generated secretomes, extracellular vesic...
|
|
WO/2024/085449A1 |
The present invention relates to a method for producing microparticles. The method for producing microparticles can produce microparticles having a uniform size and a narrow density range. Therefore, the method for producing microparticl...
|
|
WO/2024/086190A1 |
The disclosure relates to chimeric antigen receptor (CAR) specific to CD 19, vectors encoding the same, and recombinant T cells comprising the CD 19 CAR. The disclosure also includes methods of administering a genetically modified T cell...
|
|
WO/2024/086521A1 |
The present disclosure relates to methods for inducing rejuvenation in a population of glial progenitor cells and methods for treating a subject having a glial cell-related disorder. Methods include administering, to the population of ad...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/082025A1 |
The present disclosure relates generally to T cells that are modified to enhance the efficiency of adoptive cell therapy (ACT) by enhancing T cell function (e.g., CAR-T cell effector function), without affecting persistence. The present ...
|
|
WO/2024/086695A2 |
Described herein are mouse models of porphyrias, including mouse models of X- linked protoporphyria and erythropoietic protoporphyria (EPP). Immortalized human CD34+ blood cell lines expressing shRNAs targeting a human Ferrochelatase (FE...
|
|
WO/2024/082269A1 |
Provided are an application of a bispecific antibody in immune cell therapy, and a method for improving immune cell killing activity.
|
|
WO/2024/084932A1 |
[Problem] To provide a new carrier peptide fragment having cell membrane permeability. [Solution] The carrier peptide fragment disclosed herein is introduced into at least the cytoplasm of a eukaryotic cell from outside the cell and comp...
|
|
WO/2024/085261A1 |
Provided are: a novel microparticle that includes miRNA for controlling the production of nitric oxide and that is an agent for promoting the production of nitric oxide, said microparticle being capable of controlling the expression of a...
|
|
WO/2024/085252A1 |
The purpose of the present invention is to provide a novel method of preparing a cell that has undergone blastogenesis. A system (100) for preparing a cell that has undergone blastogenesis comprises an irradiation means (1, 21) which irr...
|
|
WO/2024/086191A2 |
The disclosure relates to immune cells comprising one or more vectors comprising a nucleic acid sequence encoding a chimeric antigen receptor specific for CD 19 and a nucleic acid sequence encoding an enhancer of T cell priming (e.g., IL...
|
